Biocon

Price chart

Previous close

₹367.25

Open

₹368.50

Day high

₹375.45

Day low

₹365.00

Listed on NSE since 7 April 2004.

Futures and options

Futures, 23 Nov expiry

₹369.45

Premium to the share price

+1.45 (+0.39%)

Futures open interest

18,654 contracts (−39 today)

Lot size (NOV 26)

2,500 shares

Source: NSE, 09-Nov-2026 12:04:51, delayed. Option chain · All futures · Lot sizes

Pivot levels

R3

376.77

R2

371.33

R1

368.22

CPR top

363.94

Pivot

362.78

CPR bottom

361.63

S1

359.67

S2

354.23

S3

351.12

From Friday 6 November’s high, low and close (Yahoo Finance). Arithmetic on past prices, not a forecast.

Market value

₹59,794 Cr

P/E (trailing)

122.52

EPS (trailing)

₹2.98

Price to book

1.73

Dividend yield

0.14%

Return on equity

1.0%

Debt to equity

0.42

Profit margin

2.6%

Volume today

20.33 L

Average volume

31.15 L

Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.

Source: Yahoo Finance, from annual reports. Consolidated where reported.

Source: Biocon’s results filed with NSE, consolidated (the whole group). Net profit is the share of Biocon’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.

Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.

Source: Biocon’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.

Biocon Limited, together with its subsidiaries, manufactures biotechnology products and offers research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics; Biosimilars; and Contract Research, Development and Manufacturing Organization (CRDMO) segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, central nervous system, anti-cancer/oncology, multiple sclerosis, immunosuppressants, and specialty molecules; and biosimilars products for oncology, diabetes, and immunology therapeutic areas. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal health, consumer goods, and specialty chemical industries, as well as academic institutions, non-profit organizations, and government agencies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Industry

Biotechnology

Based in

Bengaluru

Employees

16,447

Company website · Profile: Yahoo Finance

No headlines name Biocon in the last day or two.

• Dividend - Re 0.50 Per Share

  Dividend · ex-date 3 July 2026

• Dividend - Rs 0.50 Per Share

  Dividend · ex-date 4 July 2025

• Dividend - Re 0.50 Per Share

  Dividend · ex-date 5 July 2024

• Dividend - Rs 1.50 Per Share

  Dividend · ex-date 7 July 2023

• Dividend - Rs 0.50 Per Share

  Dividend · ex-date 30 June 2022 · record date 1 July 2022

• Dividend - Rs 0.50 Per Share

  Dividend · ex-date 18 July 2019 · record date 19 July 2019

• Bonus 1:1

  Bonu · ex-date 12 June 2019 · record date 13 June 2019

• Dividend- Re 1 Per Share

  Dividend · ex-date 19 July 2018 · record date 20 July 2018

Source: NSE. Latest first, 8 of 20.